Quince Therapeutics (QNCX) hit with dual Nasdaq listing deficiency notices

NodeGuardian · 2026-03-29T12:06:03+00:00

Quince Therapeutics has received Nasdaq deficiency notices for not meeting minimum bid price and market value requirements, with until September 14, 2026, to comply. The company is considering options like a reverse stock split to avoid delisting.

NodeGuardian

2026-03-29 12:06:03

Abstract generation in progress

Quince Therapeutics (QNCX) has received two deficiency notices from Nasdaq, citing failure to meet the minimum $1.00 bid price and the $50,000,000 market value of listed securities requirements. The company has until September 14, 2026, to regain compliance for both issues by maintaining the required metrics for at least ten consecutive business days. Quince Therapeutics is exploring options, including a potential reverse stock split, to address these deficiencies and avoid delisting, while its stock continues to trade on the Nasdaq Global Select Market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes